Fed’s Waller Labels March Rate Decision a “Coin Flip” as SCOTUS Tariff Ruling Reshapes Inflation Outlook
Key Takeaways Federal Reserve Governor Christopher Waller described the March interest rate decision as a "coin flip," stating that a […]
Paramount Eyes $32/Share Bid for Warner Bros. Discovery; UK Navigates US Tariff Volatility
Key Takeaways Paramount Global (PARA) is expected to submit a revised takeover offer for Warner Bros. Discovery (WBD) at $32
Trump Claims “Accidental” Empowerment After SCOTUS Tariff Ruling; Mexico GDP Exceeds Forecasts
Key Takeaways President Trump announced a new 15% global baseline tariff following a Supreme Court ruling that invalidated previous levies,
[DowJonesToday]Dow Jones Gains Momentum as Tech Giants Lead Selective Market Rally
The Dow Jones Industrial Average (^DJI) was up 230.77 (0.4672%) points today, reaching 49,625.97. The primary narrative driving the market
Geopolitical Realignment: Carney’s Indo-Pacific Tour and EU Energy Feuds Take Center Stage
Key Takeaways Canadian PM Mark Carney launches a 10-day Indo-Pacific tour (Feb 26 – Mar 7) to India, Australia, and
BoE Warns of Inflation Undershoot as Gilead Inks $7.8B Arcellx Deal and Merck Reorganizes
Key Takeaways Bank of England policymaker Alan Taylor warns of a potential inflation undershoot, signaling that two to three more
Novo Nordisk Signals Further Weight Loss Potential as EU Freezes US Trade Deal
Key Takeaways Novo Nordisk (NVO) CSO Martin Holst Lange believes the company's next-generation drug, CagriSema, has untapped weight loss potential
Market Update: S&P 500 Dips as Tariff Tensions Rise Ahead of Nvidia Earnings
Premarket Activity and Futures Movement U.S. stock futures edged lower on Monday, February 23, 2026, as investors reacted to a
Defense Secretary Hegseth Confronts Anthropic CEO Over Military AI; EU Envoys Reassess US Trade Deal
Key Takeaways Defense Secretary Pete Hegseth is set to meet Anthropic CEO Dario Amodei Tuesday morning amid threats to designate
Novo Nordisk’s CagriSema Fails to Meet Non-Inferiority Against Eli Lilly’s Tirzepatide in Key Head-to-Head Trial
Key Takeaways Novo Nordisk (NVO) announced that its next-generation obesity drug, CagriSema, failed to meet the primary endpoint of non-inferiority